Zealand Pharma A/S (CPH:ZEAL)
Denmark · Delayed Price · Currency is DKK 252.30
-74.00 (-22.68%)
Jun 8, 2026, 4:59 PM CET
Zealand Pharma Stock Forecast
Stock Price Forecast
According to 17 analysts polled by S&P Global, Zealand Pharma stock has a consensus rating of "Buy" and an average price target of kr 525.73. The average 1-year stock price forecast is 108.37% higher than the current stock price, while the lowest is kr 300.00 (+18.91%) and the highest is kr 825.00 (+226.99%).
Price Target: kr 525.73 (+108.37%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Zealand Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 8 | 8 | 8 | 8 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 5 | 5 | 5 | 5 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 17 | 17 | 17 | 17 |
Financial Forecast
Revenue This Year
4.62B
from 9.21B
Decreased by -49.87%
Revenue Next Year
4.41B
from 4.62B
Decreased by -4.58%
EPS This Year
23.00
from 90.22
Decreased by -74.50%
EPS Next Year
10.14
from 23.00
Decreased by -55.92%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is DKK.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 5.0B | ||
| Avg | 4.6B | ||
| Low | 3.4B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -45.4% | ||
| Avg | -49.9% | ||
| Low | -63.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | 23.00 | ||
| Low | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | -74.5% | ||
| Low | - |